iRadimed NASDAQ: IRMD reported record third-quarter revenue as shipments of its newly launched 3870 MR IV pump accelerated, while the company said it is moderating its production ramp to protect product quality.
Reports revenue of $24.2 million for the third quarter of 2026, which increased by $3.0 million, or 14% compared to the same period in 2025 and increased by $3.7 million or 18% compared to the second quarter of 2026. Reports GAAP diluted EPS of $0.51 and non-GAAP diluted EPS of $0.55 for the third quarter of 2026 compared to GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.47 for the second quarter of 2026.
During the third quarter of 2026, the Small Cap strategy slightly underperformed its benchmark, the Russell 2000 Index, in a period in which small cap stocks broadly declined. Top contributors include AtriCure and Red Violet; top detractors include Kodiak Gas Services and PDF Solutions. We initiated a position in IRadimed at the start of the quarter, replacing Talkspace after it was acquired.
iRadimed (NASDAQ: IRMD - Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Friday, October 30th. Analysts expect the company to announce earnings of $0.55 per share and revenue of $23.47 million for the quarter. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3
ORLANDO, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 third quarter financial results before the market opens on Friday, October 30, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
ORLANDO, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it will participate in the 5th Annual ROTH Healthcare Opportunities Conference.
iRadimed (NASDAQ: IRMD - Get Free Report) and Medline (NASDAQ: MDLN - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings. Insider and Institutional Ownership 92.3% of iRadimed shares are owned
On September 04, 2026, iRadimed Corp (IRMD) shares fell 3.8%, currently trading at $83.45. The stock has seen a notable decline, with a 52-week high of $107.90
Algert Global LLC trimmed its stake in iRadimed Corporation (NASDAQ: IRMD) by 17.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 72,994 shares of the medical equipment provider's stock after selling 15,062 shares during the period. Algert Global